Genentech Plans Manufacturing Facility in Singapore
ePT--the Electronic Newsletter of Pharmaceutical Technology
South San Francisco, CA (Mar. 28)-Genentech, Inc. announced plans to invest $140 million in 1000-liter manufacturing facility in Singapore.
South San Francisco, CA (Mar. 28)-Genentech, Inc. (www.gene.com) announced plans to invest $140 million in a 1000L manufacturing facility in Singapore.
Construction on the new facility is slated to begin in the second quarter of 2007, and the company expects it to be fully licensed by 2010. The new site will manufacture “Lucentis,” Genentech’s treatment for neovascular (wet) age-related macular degeneration, which received approval from the US Food and Drug Administration in June 2006.
Singapore recently has proven popular with other drug giants. GlaxoSmithKline (London, www.gsk.com) is building a $190-million vaccine plant there. In August 2006, Lonza (Basel, Switzerland, www.lonza.com) announced plans to build a $250-million large-scale mammalian cell-culture plant in Singapore.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
